Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)

Fig. 1

CES-D (a) and BASDAI (b) scores over time according to treatment group. Figure caption: Course of mean CES-D (a) and BASDAI (b) scores over time, by treatment group. During the open-label extension, all patients received infliximab. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CES-D, Center for Epidemiologic Studies Depression Scale; SE, standard error

Back to article page
\